1. Home
  2. NXRT vs VTAK Comparison

NXRT vs VTAK Comparison

Compare NXRT & VTAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXRT
  • VTAK
  • Stock Information
  • Founded
  • NXRT 2014
  • VTAK 2002
  • Country
  • NXRT United States
  • VTAK United States
  • Employees
  • NXRT N/A
  • VTAK N/A
  • Industry
  • NXRT Real Estate Investment Trusts
  • VTAK Medical/Dental Instruments
  • Sector
  • NXRT Real Estate
  • VTAK Health Care
  • Exchange
  • NXRT Nasdaq
  • VTAK Nasdaq
  • Market Cap
  • NXRT 849.7M
  • VTAK 3.1M
  • IPO Year
  • NXRT N/A
  • VTAK 2018
  • Fundamental
  • Price
  • NXRT $32.30
  • VTAK $2.71
  • Analyst Decision
  • NXRT Hold
  • VTAK
  • Analyst Count
  • NXRT 5
  • VTAK 0
  • Target Price
  • NXRT $39.83
  • VTAK N/A
  • AVG Volume (30 Days)
  • NXRT 173.2K
  • VTAK 159.6K
  • Earning Date
  • NXRT 10-28-2025
  • VTAK 11-12-2025
  • Dividend Yield
  • NXRT 6.32%
  • VTAK N/A
  • EPS Growth
  • NXRT N/A
  • VTAK N/A
  • EPS
  • NXRT N/A
  • VTAK N/A
  • Revenue
  • NXRT $254,446,000.00
  • VTAK $600,000.00
  • Revenue This Year
  • NXRT N/A
  • VTAK $822.86
  • Revenue Next Year
  • NXRT $4.22
  • VTAK $168.42
  • P/E Ratio
  • NXRT N/A
  • VTAK N/A
  • Revenue Growth
  • NXRT N/A
  • VTAK 37.62
  • 52 Week Low
  • NXRT $29.98
  • VTAK $2.36
  • 52 Week High
  • NXRT $48.31
  • VTAK $33.06
  • Technical
  • Relative Strength Index (RSI)
  • NXRT 43.45
  • VTAK 47.09
  • Support Level
  • NXRT $33.20
  • VTAK $2.43
  • Resistance Level
  • NXRT $34.41
  • VTAK $2.55
  • Average True Range (ATR)
  • NXRT 0.75
  • VTAK 0.13
  • MACD
  • NXRT -0.19
  • VTAK 0.06
  • Stochastic Oscillator
  • NXRT 7.31
  • VTAK 94.51

About NXRT NexPoint Residential Trust Inc.

NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Share on Social Networks: